We present a coated-tube RIA that is useful for assessment of bone resorption.
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We present a coated-tube RIA that is useful for assessment of bone resorption.
The assay uses a monoclonal antibody raised against a linear 8-amino-acid sequence (EKAH-DGGR) derived from the C-telopeptides of type I collagen. [7, 8] , and determination of a telopeptide-related fraction has been shown to constitute a sensitive and specific marker of bone resorption [9, 10] . Here, we describe an RIA based on a monoclonal antibody raised against an 8-amino-acid sequence derived from the C-telopeptides of type I collagen: EKAHDGGR.
This sequence is derived from the same site as the sequence detected in the ELISA reported earlier [8] . Because a urinary C-telopeptiderelated fraction of degradation products of type I collagen measured with the ELISA has proven to be a marker of bone resorption, an RIA also aimed at detecting such fragments represents a potentially valuable tool in the management of bone disorders. All women were monitored for spine BMD, and second morning-void urine samples were taken at 3-month intervals (0, 3, 6, 9, and 12 months) during the study.
Materials and Methods

MATERIALS
The study was performed according to the Helsinki Declaration II and the European standard for good clinical practice after approval by the regional research ethics committee. All women gave their written informed consent to participate in the study.
Ct-CROSSLAPS RIA
Balb/c mice were immunized with synthetic EKAHDGGR that had been conjugated to bovine serum albumin (BSA) in a two-step carbodiimide procedure [11] . Hybridomas were produced that were fusions of the murine spleen cells and myeloma cell line X63Ag8.653 [12] . Clone MabA7 was found to produce antibodies specific to the EKAHDGGR peptide and was thus used in the further development of the RIA. The RIA tubes were coated overnight with streptavidin (500 .tL per tube, 10 mg/L) in a solution of 0.01 mollL sodium phosphate and 0.145 molJL NaCI, pH 7.2. Before use, these tubes were washed three times in 0. frozen at -18 #{176}C until use [13] .
The monoclonal antibody (MabA7) was iodinated according to routine procedures [14] . In short, MabA7 was labeled with 1251 by a variation of the Chloramine T method, mixing 10 .tL of MabA7 solution (0.8 g/L in 10 mmol/L sodium phosphate buffer, pH 7.4, containing 0.14 mol/L NaC1) with 250 tL of 0.3 mol/L sodium phosphate buffer, pH 7.4, containing 25 g of Chloramine T and I mCi of Na'25I. After 15 s we loaded the reaction mixture onto a 0.9 x 25 cm column of Sephacryl S-300 (Pharmacia, Uppsala, Sweden) equilibrated with 10 mmol/L sodium phosphate buffer (pH 7.4) containing 0.14 mol/L NaC1, 15 mmol/L NaN3, and 1.0 g/L BSA and then eluted the column with this buffer at a flow rate of 6 mL/h. The ELISA was performed as described earlier [8, 10] . The within-and total-assay CVs were <8% in the range of concentrations covered by the calibration curve (100-6750 tg/L).
HPLC SEPARATION OF SYNTHETIC PEPTIDES
The chromatographic system (all from Waters, Milford, MA) The effluent was monitored for peptide bonds, collected in 1-mL fractions, freeze-dried, redissolved in 1 mL of phosphate-buffered saline, and assayed in the RIA.
Results
The calibrators used in the assay define the measuring range from 200 to 13500 pg/L. The detection limit (defined as the concentration corresponding to the mean absorbance of the zero calibrator minus 2SD) is 40 .tg/L. We determined within-run and total CVs (Table 1 ) based on 4 days of six determinations each of three urine samples with the same tracer preparation for the RIA. The average within-mn and total CVs were 4.4% and 5.3%, respectively. Determination of the same urine sample each day for 20 days gave a value of 3.17 ± 0.20 mgfL (mean ± SD), for a CV of 6.2%. Analytical recoveries, measured after adding increasing amounts of synthetic peptide to three different urine samples, averaged 98% ( Table 2) .
The effect of dilution of samples with a high concentration in the RIA procedure is shown in Table 3 . Samples were diluted in the zero calibrator (assay buffer). The overall average for different dilutions of the urine samples was 97% of the undiluted urine value. Repeated freezing and thawing as many as 10 times before assaying did not substantially change the urine concentration in 10 samples tested (mean ± SD percent of initial value after 10 freeze-thaw cycles: 102% ± 11%). Furthermore, in another five samples of urine without any additives, the antigen measured was stable for at least 7 days at 25 #{176}C (percent of initial value: 100% ± 16%). Figure 1 shows the specificity of the RIA towards several different synthetic peptides, including the EKAHDGGR used for immunization.
The reactivity of the RIA toward EKAHDGGR and toward the synthetic isopeptide EKAHD-j3-GGR, two molecules that differ in the linkage between an aspartate and a glycine, is shown in Fig. 2 . The linkage in EKAI-IDGGR is a peptide linkage (via the a-carbonyl of aspartate), whereas the linkage in the isomerized peptide is via the (3-carbonyl of aspartate.
The correlation between the values obtained by parallel measurements in the RIA and the ELISA ( of Ibandronate or placebo, is shown in Fig. 6 . The group receiving the bisphosphonate had a highly significant mean increase in BMD of 4.7% ± 0.7% (mean ± SE, n = 23, P <0.001), whereas the placebo group had only a small, insignificant increase (0.7% ± 0.5%, n = 25, P = 0.17). icantly decreased, by 66% (n = 23, P <0.001), in the group of women receiving 2.5 mg of Ibandronate per day.
Discussion
The present study shows that the RIA evaluated has a good performance in respect to precision, recovery, and dilution of urine samples (Tables 1, 2, and 3) . With regard to the long-term handling and assaying of the urine samples, we have shown that the samples tested can be repeatedly frozen and thawed and that the antigen in these samples is stable for at least 7 days at 25 #{176}C. Stability of urine samples is of particular interest in case patients' specimens have to be transported to a central laboratory. The data obtained with the RIA suggest that shipping of urine can take place even without refrigeration.
The specificity of the RIA towards various synthetic peptides, including the peptide used for immunization (EKAHDGGR), is shown in Fig. 1 . Inhibition studies with a peptide with deletions from the N-terminus end (AHDGGR) indicate that the epitope is located in the C-terminus of the 8-amino-acid sequence. Moreover, the presence of a free C-terminus arginine seems essential for the immunoreactivity; no reactivity was seen with a synthetic peptide prolonged by a tyrosine residue at the Cterminus, according to the sequence of the native C-telopeptide (EKAHDGGRY).
We recently showed that the CrossLaps ELISA exclusively recognizes an isomerized form of the same sequence, i.e., EKAHD-f3-GGR [15] . In the RIA, however, the monoclonal antibody used reacts almost exclusively (>98%) with the linear peptide form of the same amino acid sequence (EKAHDGGR), as seen in However, further characterization of the possible differences in the fragments of type I collagen actually excreted into urine containing the isomerized or the nonisomerized form of the EKAHDGGR sequence will probably clarify the situation.
Assays for detection of type I collagen degradation reportedly
give increased values in women after menopause [7] [8] [9] , an effect we also saw in the RIA described here (Fig. 4) . The 89% increase in the mean values measured indicates that menopausal status is reflected in an increased excretion of the C-telopeptiderelated degradation products. The ability to reflect the changes in bone resorption known to occur at menopause is essential for an assay to be used as an index of bone resorption. Application of an assay as an indicator of risk of osteoporosis is also linked to such increase,given that increased bone resorption has been related to increased risk of osteoporosis [16] . Future studies will clarify the role of the RIA as an indicator of risk of osteoporosis and fracture in the skeleton.
After bisphosphonate administration in doses ranging from 0.25 to 5 mg/day, a significant decrease in collagen-related degradation was already evident after 3 months (Fig. 5) . Values in the placebo group also decreased significantly (n = 25, P <0.01), probably because all of the women received a calcium supplement of 1000 mg/day. Intake of this amount of calcium is known to decrease the values of markers of bone turnover [17] . Values in the group of women receiving 2.5 mg/day (n = 23) decreased by 66% in 3 months to a value less than the premenopausal mean (155 ± 162 vs 227 ± 89.6 mg/mol Cr).
This dose (2.5 mg/day) therefore seems able to lower the excretion of degradation products of type I collagen to a level close to that excreted by women who are believed to be in a healthy and stable bone metabolic balance.
The effect of 2.5 mg/day bisphosphonate on the change of BMD of the spine after 12 months and the corresponding effect on the change in the excretion of the degradation products of type I collagen are shown in Fig. 6 . In this treatment group, the 66% decrease in RIA-measured degradation products values after 3 months is followed by a significant increase (4.7%, P <0.001) in the BMD of the spine after 12 months. In the placebo group, the RIA values are practically unchanged after 3 months, indicating the bone resorption continues at the same rate, i.e., a rate -90% higher than that of healthy premenopausal women. The BMD of the spine in the placebo group after 12 months is also unchanged (mean ± SE 0.7% ± 0.5%), as would be expected from women age 65 who receive 1000 mg of calcium per day. Because the data obtained by the RIA thus seem to accord well with the actual changes observed in BMD, the RIA may serve as an early indicator of the effect of bisphosphonate. Such early information may increase the compliance with the therapy and thereby secure more-efficient disease management.
In conclusion, we have shown that the RIA has a good technical performance and is easy to use. Values obtained for a group of healthy postmenopausal women are highly correlated to an established marker of bone resorption (CrossLaps ELISA) and, as would be expected, are also significantly influenced by the menopausal status of the subjects. Moreover, the RIA reflects the changes in bone metabolism known to occur during bisphosphonate therapy and may be helpful in the management of such therapy. Further studies should reveal its potential utility in other relevant clinical situations.
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